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Fibroblast growth factor 23 (FGF-23) has been identified as one of the risk factors for the 
development of cardiovascular diseases (CVDs) in chronic kidney disease (CKD) patients. 
Although FGF-23 is necessary for the maintenance of phosphate balance, it has been 
implicated in the pathogenesis of left ventricular hypertrophy, vascular dysfunction, and 
hypertension in CKD patients. FGF-23 induced alterations in intracellular calcium is 
hypothesized to be a key mechanism in the development of these CVDs. In addition, increased 
angiotensin II levels, upregulation of the renal Na+Cl- co-transporter and inhibition of 
endothelium-dependent vasorelaxation are among the potential mechanisms by which elevated 
FGF-23 levels cause hypertension in CKD. This review discusses these mechanisms and how 
these mechanistic pathways may be targeted in future experiments aimed at generating 




Systemic phosphate homeostasis is maintained through 
several hormonal mechanisms which involve fibroblast 
growth factor 23 (FGF-23), α-klotho, vitamin D and 
parathyroid hormone. FGF-23 is known to be the major 
regulator of phosphate balance (Mirams et al., 2004). 
FGF-23 is a phosphaturic hormone, which is 
synthesized by osteocytes in bone (Yoshiko et al., 
2007). Increase in serum phosphate levels stimulates 
the release of FGF-23, which decreases phosphate 
levels independent of parathyroid hormone and vitamin 
D (Shimada et al., 2005).  
In chronic kidney disease (CKD), the regulation of 
serum phosphate levels becomes significantly impaired 
resulting in rapidly increasing levels of FGF-23 in the 
circulation (Diniz and Frazao, 2013). With increasing 
evidence linking the incidence of cardiovascular 
diseases (CVDs) in CKD to elevated FGF-23 levels 
(Levin, 2003; Shuto et al., 2009; London et al., 2003), 









there is a dire need to review the potential mechanisms 
underlying this link. Understanding the mechanisms by 
which elevated FGF-23 levels leads to the occurrence 
of CVDs in CKD will significantly contribute to the 
generation of preventive measures for mitigating 
mortalities due to CVDs in CKD patients.  
This review highlights the potential mechanisms 
linking elevated FGF-23 to CVDs in CKD. First, we 
will review the physiological role of FGF-23 in 
phosphate homeostasis, and the clinical and 
epidemiological studies linking FGF-23 to CVD in 
CKD patients. 
 
FGF-23 and its role in phosphate homeostasis 
FGF-23 is a 32kDa protein, which is made up of 251 
amino acid residues, with an N-terminal region and a 
C-terminal fragment (Shimada et al., 2001). FGF-23 
exists in two forms: biologically active intact form and 
the C-terminal fragments (Fukumoto and Martin, 
2009). The biological significance of the C-terminal 
fragments is still unclear, and they are currently 
considered to be inactive (Shimada et al., 2002). 
The hormone FGF-23 primarily acts in the proximal 
tubules of the kidneys where it increases the excretion 
of phosphate by downregulating the sodium-phosphate 
transporters (Andrukhova et al., 2012). It also inhibits 
the synthesis of vitamin D by downregulating the 
expression of the 1-α-hydroxylase enzymes, and 
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increases the breakdown of vitamin D by upregulating 
the expression of 24-α-hydroxylase enzymes (Shimada 
et al., 2004). There are also reports that FGF-23 affects 
the synthesis of parathyroid hormone (Komaba and 
Fukagawa, 2010) (Fig. 1). 
The action of FGF-23 in its targets is mediated by the 
interaction with the FGF-23 receptors (FGFRs), which 
are encoded by four genes, FGFR1 – FGFR4 (Yu et al., 
2005; Li et al., 2011). There is evidence that the 
binding of FGF-23 to its co-receptor α–klotho is 
required for the FGF-23-FGFR complex to activate 
FGF-23 specific signaling pathways (Urakawa et al., 
2006). 
 
FGF-23 and CKD 
In CKD, the progressive decline in renal functions is 
hypothesized to stimulate the increase in FGF-23 as a 
compensatory response for maintaining phosphate 
balance (Isakova et al., 2011). As a result, FGF-23 
levels increases even before the occurrence of 
phosphate imbalance. The stages of CKD (stages 1 – 5) 
are characterized by progressively decreasing 
glomerular filtration rate (GFR). Pavik et al. (2013) 
showed that from early CKD (stage 2), the levels of 
FGF-23 begin to increase exponentially as the GFR 
decreases. Their findings also revealed that excess 
serum phosphate is only observed in late stages of CKD 
(stages 4 and 5). 
 
Association of FGF-23 and CVDs in CKD 
There is increasing rate of CVD mortality and 
morbidity in CKD patients compared with the general 
population. Approximately 40% of patients in early 
CKD stages, and up to 80% of patients in late CKD 
stages manifest left ventricular hypertrophy (Levin et 
al., 1996). Arterial calcification has also been reported 
in early CKD stages, which becomes very significant in 




Fig. 1: Physiological functions of FGF-23. FGF-23 is released in response to high extracellular phosphate levels. Circulating 
FGF-23 downregulates the renal phosphate transporters, NaPi-IIa and NaPi-IIc; inhibits the release of active vitamin D and 
inhibits the synthesis of parathyroid hormones. These actions of FGF-23 restore extracellular phosphate levels back to normal. 
 
 
The prevalence of hypertension has also been shown to 
be higher among patients with CKD (U.S Renal Data 
System, 2010). The U.S Renal Data System (USRDS) 
in 2010 reported that hypertension occurs in 
approximately 23.3% of individuals without CKD, 
35.5% of stage 1 CKD- and 84.1% of stage 4-5 CKD 
patients.  
Increased FGF-23 levels in CKD patients has been 
suggested as a novel risk factor for cardiovascular 
disease events (Seiler et al., 2010; Jean et al., 2009). 
Elevated FGF-23 levels, which is a consequence of 
disturbances in mineral metabolism has been shown to 
be associated with CKD progression (Noordzij et al., 
2008). Kramer et al. (2005) reported a link between 
these disturbances in mineral metabolism and 
cardiovascular morbidity and mortality in CKD, 
possibly as a result of cardiovascular calcification. 
A better understanding of the potential mechanisms 
underlying the occurrence of CVDs in CKD patients 
may prove invaluable for future investigation. 
 
Potential mechanisms linking elevated FGF-23 and 
CVDs in CKD 
FGF-23 and left ventricular hypertrophy (LVH) 
Recent findings have shown that the pathological 
cardiac hypertrophic effect of FGF-23 is mediated by 
FGFR-dependent activation of the calcineurin-nuclear 
factor activated T cells (NFAT) signaling pathway 
(Faul et al., 2011). Calcineurin is a calcium-calmodulin 
activated protein, which is a serine/threonine-specific 
phosphatase that is activated by persistent elevation of 
intracellular calcium concentration (Klee et al., 1998; 
Dolmetsch et al., 1997). As a phosphatase, activated 
calcineurin dephosphorylate the members of the NFAT  
FGF-23 and chronic kidney disease 
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Fig. 2. Pathophysiology of cardiovascular diseases mediated by FGF-23 in CKD. A) High FGF-23 levels result in 
increased intracellular and extracellular Ca2+ levels. Excess intracellular Ca2+ in the left ventricle of the heart activates the 
calcineurin-NFAT signaling pathway, which results in left ventricular hypertrophy. Excess extracellular Ca2+ due to 
secondary hyperparathyroidism in CKD patients results in vascular calcification. B) High FGF-23 levels directly activate the 
Na+Cl- co-transporter (NCC) expression in the renal distal tubule, stimulate the renin-angiotensin aldosterone system 
(RAAS), and also initiate oxidative stress. Increased sodium retention due to increased NCC and aldosterone activities as 
well as increased vascular resistance due to the vascular effects of angiotensin II and free radicals result in hypertension. 
 
 
expressed in the myocardium, thus activating the 
hypertrophic pathway (Wilkins et al., 2002). This FGF-
23-FGFR activation of the calcineurin-NFAT signaling 
pathway was shown to be independent of the FGF-23 
co-receptor α-klotho (Faul et al., 2011). This rules out 
the involvement of α-klotho in the mechanisms 
underlying FGF-23 mediated cardiac hypertrophy. 
A more recent report suggests that FGF-23 directly 
regulates intracellular calcium concentration in the 
myocardium (Touchberry et al., 2013), and this may 
play a role in activating the calcineurin-NFAT 
pathway; thus, implicating FGF-23 in the pathogenesis 
of LVH. 
Furthermore, targeting the activation of calcineurin in 
CKD patients may prove invaluable in the prevention 
of LVH. Since calcineurin is physiologically activated  
 
by sustained elevations in intracellular calcium levels, 
it is plausible that hypercalcaemia in CKD may 
contribute to pathological LVH. The use of calcineurin 
inhibitors is not considered a therapeutic option in 
preventing LVH due to their nephrotoxic nature (Ojo et 
al., 2003). Further investigations on the potential role  
 
of FGFR blockers in the prevention of LVH in CKD 
may significantly advance knowledge about the 
pathogenicity of LVH in CKD. 
 
FGF-23, vascular dysfunction and hypertension 
Vascular calcification, a common form of vascular 
dysfunction, and hypertension are among the various 
CVDs associated with CKD. While hypertension has 
been strongly linked with elevated FGF-23 in normal 
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and CKD patients (Gutierrez et al., 2011), it is still 
unclear if elevated FGF-23 levels directly result in 
vascular calcification (Kendrick and Chonchol, 2011). 
The inhibition of vitamin D synthesis and the increased 
excretion of phosphate by FGF-23 suggest that FGF-23 
may not directly play a role in vascular calcification. 
However, the extremely high levels of parathyroid 
hormone due to secondary hyperparathyroidism in 
CKD may be responsible for the development of 
vascular calcification in CKD patient. The role of FGF-
23 in the activation of the renin-angiotensin aldosterone 
system (RAAS), renal sodium retention, and vascular 
reactivity may contribute to the development of 
hypertension in CKD. 
Recent reports suggest that FGF-23 directly stimulates 
the RAAS by inhibiting the expression of angiotensin-
converting enzyme 2 (ACE2)(Dai et al., 2012). ACE2 
is an exopeptidase that catalyses the conversion of 
angiotensin I to angiotensin I-9 (Donoghue et al., 
2000). It also catalyses the conversion of angiotensin II 
to angiotensin I-7 (Keidar et al., 2007). The net effect 
of ACE2 is to reduce circulating levels of angiotensin 
II. Hence, the suppression of ACE2 expression by 
FGF-23 will lead to increased levels of angiotensin II in 
the circulation. Angiotensin II acts on type 1 
angiotensin II receptors to stimulate vasoconstriction, 
thus directly increasing the total peripheral resistance in 
blood vessels. Stimulation of the type 1 angiotensin II 
receptors by angiotensin II activates phospholipase C, 
which hydrolyses phosphatidylinositol-4, 5- 
biphosphate to generate inositol-1,4,5-triphosphate and 
diacylglycerol. Inositol-1,4,5-triphosphate triggers the 
release of calcium from intracellular stores resulting in 
an increase in intracellular calcium. Thus, the resultant 
effect of suppressing ACE2 expression by FGF-23 is 
increased levels of intracellular calcium, suggesting 
that FGF-23 induced increase in intracellular calcium 
levels may play a key role in the development of 
vascular dysfunction and hypertension in CKD. 
Angiotensin II is also a potent stimulus for aldosterone 
secretion. Taken together, these mechanisms support 
the role of FGF-23 in the development of hypertension 
in CKD. 
Emerging evidence suggests that FGF-23 directly 
regulate the abundance of the Na+Cl- co-transporter 
(NCC) in the apical membrane of the renal distal 
tubules (Andrukhova et al., 2014). Loss-of-function 
mutations and gain-of-function studies by Andrukhova 
et al. (2014) showed that FGF-23 interacts with its co-
receptor α-klotho to directly upregulate distal tubular 
NCC expression. Increased Na+retention due to NCC 
upregulation results in a consequent increase in plasma 
volume and hypertension. 
Another potential mechanism by which FGF-23 affect 
vascular function and blood pressure is its action on 
vascular smooth muscle activity. Studies on the 
localization of FGFRs and α-klotho in vascular tissue 
have shown that the expression of α-klotho is 
significantly lower than the expression levels of the 
FGFR1-4 (Donate-Correa et al., 2013; Lindberg et al., 
2013). This suggests that the effects of FGF-23 on 
vascular function may be independent of α-klotho. 
FGF-23 has been shown to directly impair 
endothelium-dependent vasorelaxation by reducing the 
bioavailability of nitric oxide (Silswal et al., 2014). To 
gain more insight into the potential mechanisms 
underlying this role of FGF-23 on nitric oxide 
bioavailability, reports by Six et al. (2014) indicate that 
endothelial nitric oxide synthase is unaffected by FGF-
23 (Figs 1 and 2). 
Furthermore, oxidative stress has been suggested to be 
a vital link between CVD and CKD (Andrukhova et al., 
2014). With previous reports that oxidative stress 
induces endothelial dysfunction (Capellini et al., 2010), 
it is plausible that excess FGF-23 in CKD causes 
oxidative stress, which then affect the bioavailability of 
nitric oxide. Beckman and Koppenol (1996) previously 
hypothesized that oxidative stress increases the levels 
of superoxide, which rapidly combines with nitric 
oxide and converts it to peroxynitrite. It has recently 
been shown that an increased level of superoxide was 
observed following the preincubation of primary 
endothelial cells and aortic rings with FGF-23 
(Andrukhova et al., 2014). Taken together, these 
findings suggest that FGF-23 reduces the 
bioavailability of nitric oxide by increasing the 
abundance of superoxide. 
 
CONCLUSION 
Increased angiotensin II levels, increased Na+ retention 
and inhibition of endothelium-dependent 
vasorelaxation by FGF-23 are among the potential 
mechanisms by which elevated FGF-23 levels cause 
hypertension in CKD patients. Intracellular calcium 
plays a central role in FGF-23 induced LVH. 
Furthermore, investigating the role of FGF-23 in the 
regulation of intracellular calcium levels in vascular 
smooth muscle cells may reveal novel signaling 
pathways that may be targeted in the prevention of 
vascular dysfunction in CKD. 
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